Clinical Omics – News and Features

Researchers have uncovered 166 prognostic biomarkers through machine learning analysis of long non-coding RNAs.

A team of researchers has developed the largest and most comprehensive molecular map to date of lung squamous cell carcinoma. The database, which brings proteomic, transcriptomic and genomic data together, can be used to find potential new drug targets and identify underlying disease mechanisms related to therapy resistance.

In the early 20th century, mass spectrometry (MS) was used to measure the mass of atoms and demonstrate the existence of isotopes. Now, MS is used to study a broad range of molecules including small hydrocarbons, proteins, peptides, carbohydrates and DNA.

Researchers have analyzed more than 8,000 proteins in detail from fixed samples of lung cancer tissue using mass spectrometers.

Mass spectrometry (MS) is a key technique in analytical chemistry and plays a role in many varied aspects of day-to-day life. In this article, we take a look at the fundamentals of MS, how it works, variations that can be used at each stage of the process and how they can be combined to suit different sample types or analytical questions.

In this article, we explore multiomic approaches to COVID-19 research and explore some of the computational and statistical tools being developed to support multiomic analyses.

More than 1,200 people with rare diseases have received a diagnosis thanks to the integration of large-scale genomics into the Stockholm region's healthcare system.

Researchers have created a rapid genome sequencing strategy for the coronavirus.

In 2020, we celebrate 90% of the human proteome being mapped by the Human Proteome Project (HPP). In this article, we reflect on the history of this endeavor and the future of the proteomics field, speaking with individuals close to the project.

Thermo Fisher Scientific announced agreements with AstraZeneca and the University of Nebraska Medical Center that will showcase new workflows to improve the throughput, robustness and standardization of clinical biomarker analysis.